Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...
CPT copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. CMS has approved Second Sight ...
USC and Second Sight Medical Products Inc., the developer of retinal prostheses for treating blindness, are expanding the clinical trial of an advanced retinal prosthesis into Europe. The announcement ...
The US Food and Drug Administration (FDA) has announced the approval of a new medical device intended to treat a rare disease population through the use of a retinal implant. The device, Second Sight ...
A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...
Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...
This undated product image provided by Second Sight Medical Products shows a new implantable device that takes the place of damaged cells inside the eye. The Food and Drug Administration on Thursday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results